Large-scale DNA methylation profiling of urological cancers identifies shared and cancer-specific methylation signatures, and reveals differentially activated pathways for therapeutic targeting

Vera Constâncio; João Lobo; Antonio Gomez; João Ramalho-Carvalho; Isa Carneiro; Rui Freitas; Manuel Esteller; Rui Henrique; Carmen Jerónimo

doi:10.1002/ctm2.70488

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (10) : e70488 DOI: 10.1002/ctm2.70488

LETTER TO THE JOURNAL

Large-scale DNA methylation profiling of urological cancers identifies shared and cancer-specific methylation signatures, and reveals differentially activated pathways for therapeutic targeting

Vera Constâncio ¹^,²^,³
, João Lobo ¹^,²^,⁴^,⁵
, Antonio Gomez ⁶
, João Ramalho-Carvalho ¹^,²
, Isa Carneiro ¹^,²^,⁴
, Rui Freitas ¹^,²^,⁷
, Manuel Esteller ⁸^,⁹^,¹⁰^,¹¹
, Rui Henrique ¹^,²^,⁴^,⁵
, Carmen Jerónimo ¹^,²^,⁵

Author information +

¹. Cancer Biology & Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

². Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), Porto, Portugal

³. Doctoral Program in Biomedical Sciences, ICBAS - School of Medicine & Biomedical Sciences, University of Porto, Porto, Portugal

⁴. Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

⁵. Department of Pathology and Molecular Immunology, ICBAS - School of Medicine & Biomedical Sciences, University of Porto, Porto, Portugal

⁶. Department of Biosciences, Faculty of Sciences and Technology (FCT), University of Vic – Central University of Catalonia (UVic-UCC), Barcelona, Catalonia, Spain

⁷. Urology Clinic, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal

⁸. Cancer Epigenetics Group, Josep Carreras Leukemia Research Institute (IJC), Badalona, Catalonia, Spain

⁹. Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain

¹⁰. Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain

¹¹. Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain

carmenjeronimo@ipoporto.min-saude.pt

Show less

History +

PDF

Cite this article

Download citation ▾

Vera Constâncio, João Lobo, Antonio Gomez, João Ramalho-Carvalho, Isa Carneiro, Rui Freitas, Manuel Esteller, Rui Henrique, Carmen Jerónimo. Large-scale DNA methylation profiling of urological cancers identifies shared and cancer-specific methylation signatures, and reveals differentially activated pathways for therapeutic targeting. Clinical and Translational Medicine, 2025, 15(10): e70488 DOI:10.1002/ctm2.70488

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3): 229-263.

[2]	Dy GW, Gore JL, Forouzanfar MH, Naghavi M, Fitzmaurice C. Global burden of urologic cancers, 1990–2013. Euro Urol. 2017; 71(3): 437-446.

[3]	Turajlic S, Xu H, Litchfield K, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal. Cell. 2018; 173(3): 595-610. e11.

[4]	Lindskrog SV, Prip F, Lamy P, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. 2021; 12(1): 2301.

[5]	Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability – an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010; 11(3): 220-228.

[6]	Constancio V, Lobo J, Sequeira JP, Henrique R, Jeronimo C. Prostate cancer epigenetics – from pathophysiology to clinical application. Nat Rev Urol. 2025; 22(7): 447-469.

[7]	Henrique R, Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol. 2004; 46(5): 660-669. discussion 9.

[8]	Martinez-Gonzalez LJ, Antunez-Rodriguez A, Vazquez-Alonso F, Hernandez AF, Alvarez-Cubero MJ. Genetic variants in xenobiotic detoxification enzymes, antioxidant defenses and hormonal pathways as biomarkers of susceptibility to prostate cancer. Sci Total Environ. 2020; 730: 138314.

[9]	Hushmandi K, Einollahi B, Saadat SH, et al. Amino acid transporters within the solute carrier superfamily: underappreciated proteins and novel opportunities for cancer therapy. Mol Metab. 2024; 84: 101952.

[10]	Paco A, de Bessa Garcia SA, Freitas R. Methylation in HOX clusters and its applications in cancer therapy. Cells. 2020; 9(7): 1613.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.